The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity

详细信息    查看全文

• 作者：Christian Hess ; Dario Neri
• 关键词：Interleukin 13 ; Armed antibody ; Cytokine ; Targeting ; Cancer therapy
• 刊名：Cancer Immunology, Immunotherapy
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：64
• 期：5
• 页码：635-644
• 全文大小：1,451 KB
• 参考文献：1.Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 171:5051-063. doi:10.-049/?jimmunol.-71.-0.-051 View Article PubMed
  2.Welander CE (1987) Overview of preclinical and clinical-studies of interferon Alfa-2b in combination with cytotoxic drugs. Invest New Drug 5:S47–S59. doi:10.-007/?BF00207263
  3.Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20:264-69. doi:10.-038/?nbt0302-264 View Article PubMed
  4.Hess C, Venetz D, Neri D (2014) Emerging classes of armed antibody therapeutics against cancer. Med Chem Commun 5:408-31. doi:10.-039/?C3MD00360D View Article
  5.Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133:751-58. doi:10.-038/?jid.-012.-76 View Article PubMed
  6.Hemmerle T, Neri D (2014) The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer. Int J Cancer 134:467-77. doi:10.-002/?ijc.-8359 View Article PubMed
  7.Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59:612-18. doi:10.-002/?ijc.-910590507 View Article PubMed
  8.Borsi L, Castellani P, Allemanni G, Neri D, Zardi L (1998) Preparation of phage antibodies to the ED-A domain of human fibronectin. Exp Cell Res 240:244-51. doi:10.-006/?excr.-998.-946 View Article PubMed
  9.Frey K, Fiechter M, Schwager K, Belloni B, Barysch MJ, Neri D, Dummer R (2011) Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol 20:685-88. doi:10.-111/?j.-600-0625.-011.-1314.?x View Article PubMed
  10.Moschetta M, Pretto F, Berndt A et al (2012) Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res 72:1814-824. doi:10.-158/-008-5472.?CAN-11-1919 View Article PubMed
  11.Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33:1718-722. doi:10.-016/?j.?leukres.-009.-6.-25 View Article PubMed
  12.Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5:201ra118. doi: 10.-126/?scitranslmed.-006221
  13.Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rosli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405-413. doi:10.-002/?ijc.-3408 View Article PubMed
  14.Pasche N, Neri D (2012) Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17:583-90. doi:10.-016/?j.?drudis.-012.-1.-07 View Article PubMed
  15.Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147-59. doi:10.-038/?nrd1957 View Article PubMed
  16.Kontermann RE (2012) Antibody-cytokine fusion proteins. Arch Biochem Biophys 526:194-05. doi:10.-016/?j.?abb.-012.-3.-01 View Article PubMed
  17.Pasche N, Wulhfard S, Pretto F, Carugati E, Neri D (2012) The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res 18:4092-103. doi:10.-158/-078-0432.?CCR-12-0282 View Article PubMed
  18.Gutbrodt KL, Casi G, Neri D (2014) Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 13:1772-776. doi:10.-158/-535-7163.?MCT-14-0105 View Article PubMed
  19.de Vries JE (1998) The role of IL-13 and its receptor in allergy and inflammatory responses. J Allergy Clin Immunol 102:165-69. doi:10.-016/?S0091-6749(98)70080-6 View Article PubMed
  20.Hancock A, Armstrong L, Gama R, Millar A (1998) Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 18:60-5. doi:10.-165/?ajrcmb.-8.-.-627 View Article PubMed
  21.de Waal MalefytR, Abrams JS, Zurawski SM et al (1995) Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-tra
• 作者单位：Christian Hess (1)
  Dario Neri (1)
  
  1. Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zurich (ETH Zürich), Vladimir-Prelog-Weg 1-5/10, 8093, Zurich, Switzerland
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Cancer Research
  Immunology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0851

文摘

We describe the expression and in vivo characterization of an antibody–cytokine fusion protein, based on murine Interleukin-13 (IL13) and the monoclonal antibody F8, specific to the alternatively spliced extra domain A of fibronectin, a marker of neo-angiogenesis. The IL13 moiety was fused at the C-terminal extremity of the F8 antibody in diabody format. The resulting F8-IL13 immunocytokine retained the full binding properties of the parental antibody and cytokine bioactivity. The fusion protein could be expressed in mammalian cells, purified to homogeneity and showed a preferential accumulation at the tumor site. When used as single agent at doses of 200?μg, F8-IL13 exhibited a strong inhibition of tumor growth rate in two models of cancer (F9 teratocarcinoma and Wehi-164), promoting an infiltration of various types of leukocytes into the neoplastic mass. This anticancer activity could be potentiated by combination with an immunocytokine based on the F8 antibody and murine IL12, leading to complete and long-lasting tumor eradications. Mice cured from Wehi-164 sarcomas acquired a durable protective antitumor immunity, and selective depletion of immune cells revealed that the antitumor activity was mainly mediated by cluster of differentiation 4-positive T cells. This study indicates that IL13 can be efficiently delivered to the tumor neo-vasculature and that it mediates a potent anticancer activity in the two models of cancer investigated in this study. The observed mechanism of action for F8-IL13 was surprising, since immunocytokines based on other payloads (e.g., IL2, IL4, IL12 and TNF) eradicate cancer by the combined contribution of natural killer cells and cluster of differentiation 8-positive T cells.